ClinicalTrials.Veeva

Menu

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

C

Chong Kun Dang

Status and phase

Completed
Phase 1

Conditions

Hypertension
Dyslipidemias

Treatments

Drug: CKD-828, D097, D337
Drug: CKD-348(6)

Study type

Interventional

Funder types

Industry

Identifiers

NCT06112678
A86_13BE2314

Details and patient eligibility

About

A phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348(6).

Enrollment

63 patients

Sex

All

Ages

19+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy adult volunteers aged ≥ 19 years.

  2. Body weight ≥55kg with calculated body mass index (BMI) of 18 to 30 kg/m2

  3. Those who meet the blood pressure criteria during screening tests:

    • Systolic Blood Pressure: 90 to 139 mmHg
    • Diastolic Blood Pressure: 60 to 89 mmHg
  4. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.

  5. Those who are eligible for clinical trials based on laboratory (hematology, blood chemistry, serology, urology) and ECG results at screening.

  6. Those who agree to contraception during the participation of clinical trial.

  7. Those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion criteria

  1. Those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs.

  2. Those who take barbiturate and any related drugs which may cause induction or inhibition of drug metabolism within 1 month and those who take drug could affect to clinical trial within 10 days before the first administration of investigational products.

  3. Those who donated whole blood or apheresis within 8 weeks or 4 weeks respectfully, or received blood transfusion within a month.

  4. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.

  5. Those who exceed an alcohol and cigarette consumption criteria write below within 1 month before the first administration of investigational products.

    • Alcohol: Man - 21 glasses/week, Woman - 14 glasses/week (1glass: Soju 50mL, Wine 30mL, or beer 250mL)
    • Smoking: 20 cigarettes/day
  6. Those who have any history of diabetic mellitus, nephropathy, biliary obstruction, shock, angioedema, cardiac insufficiency, dihydropyridine sensitivity, unstable angina, hypothyroidism and hypersensitive to Sunset yellow FCF.

  7. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption.

  8. Those who are deemed insufficient to participate in this clinical trial by investigators.

  9. Woman who are pregnant or breastfeeding.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

63 participants in 2 patient groups

Sequence 1
Experimental group
Description:
Period 1: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 3: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 4: CKD-348(6) - A single oral dose of 1 tablet under fasting condition
Treatment:
Drug: CKD-828, D097, D337
Drug: CKD-348(6)
Sequence 2
Experimental group
Description:
Period 1: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 2: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-348(6) - A single oral dose of 1 tablet under fasting condition Period 4: CKD-828, D097, D337- A single oral dose of 3 tablets under fasting condition
Treatment:
Drug: CKD-828, D097, D337
Drug: CKD-348(6)

Trial contacts and locations

1

Loading...

Central trial contact

Seung-Hyun Kang, M.D., Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems